Sustained CD4 and CD8 lymphopenia after rituximab maintenance therapy following bendamustine and rituximab combination therapy for lymphoma

Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study

(2014) I. W. Flinn et al.   BLOOD

B Cell Depletion Curtails CD4+ T Cell Memory and Reduces Protection against Disseminating Virus Infection

(2014) I. Misumi et al.   JOURNAL OF IMMUNOLOGY

Rituximab-Induced T Cell Depletion in Patients With Rheumatoid Arthritis: Association With Clinical Response

(2013) J. Mélet et al.   ARTHRITIS AND RHEUMATISM

Severe and prolonged lymphopenia observed in patients treated with bendamustine and erlotinib for metastatic triple negative breast cancer

(2013) Rachel M. Layman et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Multicenter Phase II Study of Bendamustine Plus Rituximab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

(2013) Ken Ohmachi et al.   JOURNAL OF CLINICAL ONCOLOGY

Long-term efficacy and safety of pre-emptive maintenance therapy with rituximab in granulomatosis with polyangiitis: results from a single centre

(2013) Emilio Besada et al.   RHEUMATOLOGY

Severe CMV reactivation and gastritis during treatment of follicular lymphoma with bendamustine

(2011) Seah H. Lim et al.   ANNALS OF HEMATOLOGY

Pneumocystis jirovecii pneumonia as a complication of bendamustine in a patient receiving bendamustine plus rituximab for marginal zone lymphoma

(2011) Stephanie J. Carter et al.   LEUKEMIA RESEARCH

Optimal Use of Bendamustine in Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphomas, and Multiple Myeloma: Treatment Recommendations From an International Consensus Panel

(2010) Bruce D. Cheson et al.   Clinical Lymphoma Myeloma & Leukemia